Natural killer cells are coated with Fc receptors and can be activated through the binding of antibodies to these Fc receptors. Once activated, natural killer cells engage in antibody dependent cellular cytotoxicity (ADCC), wherein a target cell is lysed by the natural killer cells, causing the target cell to secrete cytokines that recruit adaptive immune cells.
Researchers at the National Cancer Institute (NCI) developed fully human single domain antibodies targeting CD16A, a Fc receptor found on the surface of natural killer cells. The invention antibodies have high binding affinity and specificity to CD16A. Researchers have incorporated the invention antibodies in bispecific killer cell engagers (BiKEs) for targeting HIV-1. However, these single domain antibodies could also be used in the treatment of a variety of other diseases, including cancer.
• Antibody-based therapeutic for treatment of cancer
• Antibody-based therapeutic against HIV-1
• Fully human antibodies are likely to have less toxicity associated with them and thus, an improved drug safety profile
• Potential use in a variety of therapeutic applications where ADCC is a necessary component of treatment
• BiKEs could overcome self-inhibitory signals
• Relevance to a wide range of cancers
Dimiter Dimitrov (NCI), Wei Li (NCI), Weizao Chen (NCI)
- U.S. Provisional: U.S. Provisional Patent Application Number 62/379,582, Filed 25 Aug 2016